Financial Information
We introduce ADBIOTECH’s technology intended to replace vaccines
and antibiotics.
(Unit: KRW in millions)
Sales
Operating profit
Net profit
Income Statements(Unit: KRW in millions)
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Operating profit | -4,779 | -2,580 | -2,908 |
| Other gains | 1 | 2 | 3 |
| Other losses | 284 | 2,882 | 1,483 |
| Finance costs | 1,656 | 1,955 | 5,147 |
| Finance income | 9,404 | 4,962 | 872 |
| Cost Of Sales | 3,096 | 2,967 | 3,853 |
| Net profit | 2,686 | -2,454 | -8,663 |
| Sales | 10,650 | 8,493 | 10,521 |
(Unit: KRW in millions)
Total Assets
Total liabilities
Total equity
Financial Position(Unit: KRW in millions)
| Item | 2019 | 2020 | 2021 |
|---|---|---|---|
| Total Assets | 30,993 | 27,703 | 23,097 |
| Current Assets | 13,859 | 14,445 | 8,527 |
| Non-current Assets | 17,134 | 13,258 | 14,570 |
| Capital surplus | 27,257 | 27,257 | 27,257 |
| Total equity | 16,324 | 13,932 | 6,377 |
| Share capital | 4,570 | 4,570 | 4,570 |
| Retained earnings | -13,442 | -15,896 | -24,559 |
| Current liabilities | 11,629 | 10,238 | 12,558 |
| Total liabilities | 14,669 | 13,771 | 16,721 |
| Non-Current liabilities | 3,040 | 3,533 | 4,163 |